ARTICLE | Financial News
Roivant’s urology subsidiary files for $150M IPO
July 20, 2018 4:56 PM UTC
Urovant Sciences Ltd. (London, U.K) proposed on July 13 to raise up to $150 million in an IPO on NASDAQ underwritten by J.P. Morgan, Jefferies and Cowen. The urology play is a wholly owned subsidiary of Roivant Sciences GmbH (Basel, Switzerland), which will be Urovant's controlling shareholder following the offering...
BCIQ Target Profiles